REPL vs BCAT Comparison

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

BlackRock Capital Allocation Trust, now BlackRock Capital Allocation Term Trust, is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. The Trust invests in a portfolio of both equity and debt securities of companies from different sectors such as Information Technology, Financials, Industrials, Communication, Health Care, etc. It also utilizes an option-writing (selling) plan in an effort to generate current gains from option premiums and to enhance its risk-adjusted returns.